eFFECTOR Therapeutics Inc. (NASDAQ:EFTR) saw an upside of 5.77% to close Friday at $0.69 after adding $0.04 on the day. The 5-day average trading volume is 333,460 shares of the company’s common stock. It has gained $0.7293 in the past week and touched a new high 4 times within the past 5 days. An average of 552,815 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,136,416.
EFTR’s 1-month performance is -10.71% or -$0.0835 on its low of $0.6020 reached on 08/11/23. The company’s shares have touched a 52-week low of $0.34 and high of $1.48, with the stock’s rally to the 52-week high happening on 06/06/23. YTD, EFTR has achieved 60.78% or $0.2599 and has reached a new high 10 times. However, the current price is down -53.55% from the 52-week high price.
Valuation Metrics
EFTR stock has a beta of 0.39. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 26.71 while the price-to-book (PB) in the most recent quarter is 13.75.
eFFECTOR Therapeutics Inc.’s quick ratio for the period ended June 29 was 1.10, with the current ratio over the same period at 1.10. The trailing 12-month EBITDA margin is -910.50%. The firm’s gross profit as reported stood at $35.96 million against revenue of $3.55 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 17.22% to -$8.36 million, while revenue of -$10.01 million was -19.74% off the previous quarter. Analysts expected EFTR to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.17, representing a 15.00% surprise. EBITDA for the quarter stood at more than -$7.91 million. EFTR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 24.31 million, with total debt at $20.41 million. Shareholders hold equity totaling $61.77 million.
Let’s look briefly at eFFECTOR Therapeutics Inc. (EFTR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 46.71% to suggest the stock is trending Neutral, with historical volatility in this time period at 75.30%.
The stock’s 5-day moving average is $0.6654, reflecting a +2.93% or $0.0196 change from its current price. EFTR is currently trading -8.46% above its 20-day SMA, +89.24% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -46.71% and SMA200 by+12.21%.
Stochastic %K and %D was 26.01% and 26.16% and the average true range (ATR) pointed at 0.0675. The RSI (14) points at 45.30%, while the 14-day stochastic is at 40.22% with the period’s ATR at 0.0719. The stock’s 9-day MACD Oscillator is pointing at -0.0190 and -0.0374 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for eFFECTOR Therapeutics Inc. (NASDAQ: EFTR), Stifel downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for EFTR stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate EFTR as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is EFTR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.40 and a high of $10.00, with their median price target at $6.25. Looking at these predictions, the average price target given by analysts is for eFFECTOR Therapeutics Inc. (EFTR) stock is $6.98.
